abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Acute Myeloid Leukemia · Breast Cancer
First People's Hospital
The First People's Hospital of Lianyungang
First People's Hospital drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
SAN DIEGO, CA, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- SAN DIEGO, CA, CN
- Programs
- 1136
- Drugs
- 626
- Patents
- 123
First People's Hospital pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
First People's Hospital drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
abatacept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: T-lymphocyte activation antigen CD80.
- Target
- T-lymphocyte activation antigen CD80
- Mechanism
- T-lymphocyte activation antigen CD80 inhibitor
-
US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal-associated protein 25 inhibitor
-
acalabrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Carbonic anhydrase 1.
- Target
- Carbonic anhydrase 1
- Mechanism
- Carbonic anhydrase XII inhibitor
-
US regulatory status: approved. Mechanism: Glutathione precursor.
- Mechanism
- Glutathione precursor
-
US regulatory status: approved. Molecular target: Retinoid receptor.
- Target
- Retinoid receptor
- Mechanism
- Retinoid receptor agonist
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
aflibercept
Sensory organs (S01)US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
alirocumab
Cardiovascular system (C10)US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.
- Target
- Proprotein convertase subtilisin/kexin type 9
- Mechanism
- Subtilisin/kexin type 9 inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in First People's Hospital's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
alogliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Mechanism: Dipeptidyl peptidase IV inhibitor.
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP1 subtype.
- Target
- Prostaglandin E2 receptor EP1 subtype
- Mechanism
- Prostanoid EP1 receptor agonist
-
US regulatory status: approved. Molecular target: Tissue-type plasminogen activator.
- Target
- Tissue-type plasminogen activator
- Mechanism
- Tissue-type plasminogen activator exogenous protein
-
US regulatory status: approved. Mechanism: Antacid.
- Mechanism
- Antacid
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
ambrisentan
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in First People's Hospital's portfolio.
-
Development asset linked to First People's Hospital in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in First People's Hospital's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Platelet-derived growth factor receptor beta.
- Target
- Platelet-derived growth factor receptor beta
- Mechanism
- Platelet-derived growth factor receptor beta inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in First People's Hospital's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
aprepitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
US regulatory status: approved. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
- Target
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
aumolertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in First People's Hospital's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in First People's Hospital's portfolio.
-
avapritinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Platelet-derived growth factor receptor alpha.
- Target
- Platelet-derived growth factor receptor alpha
- Mechanism
- Stem cell growth factor receptor inhibitor
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
basiliximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
bedaquiline
Antiinfectives for systemic use (J04)Antiinfectives for systemic use (J04) compound in First People's Hospital's portfolio.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Hepatitis C virus serine protease, NS3/NS4A.
- Target
- Hepatitis C virus serine protease, NS3/NS4A
- Mechanism
- Hepatitis C virus serine protease, NS3/NS4A inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records. Mechanism: Probiotic.
- Mechanism
- Probiotic
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
bivalirudin
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
blinatumomab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- T cell surface glycoprotein CD3 cross-linking agent
-
botulinum toxin type a
Musculo-skeletal system (M03)Musculo-skeletal system (M03) compound in First People's Hospital's portfolio. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
brentuximab vedotin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1A.
- Target
- 5-hydroxytryptamine receptor 1A
- Mechanism
- Serotonin 1a (5-HT1a) receptor partial agonist
-
busulfan
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
canagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
celecoxib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor beta.
- Target
- Estrogen receptor beta
- Mechanism
- Estrogen receptor beta modulator
-
US regulatory status: approved. Molecular target: Bile acids.
- Target
- Bile acids
- Mechanism
- Bile acids sequestering agent
-
cholic acid
Alimentary tract and metabolism (A05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
ciclosporin
Sensory organs (S01)Sensory organs (S01) compound in First People's Hospital's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
US regulatory status: approved. Molecular target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
- Target
- cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
- Mechanism
- Phosphodiesterase 3A inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in First People's Hospital's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in First People's Hospital's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
US regulatory status: approved. Molecular target: Cystine.
- Target
- Cystine
- Mechanism
- Cystine reducing agent
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
dabigatran etexilate
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in First People's Hospital's portfolio. Mechanism: Thrombin inhibitor.
- Mechanism
- Thrombin inhibitor
-
US regulatory status: approved. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
darolutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
degarelix
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in First People's Hospital's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in First People's Hospital's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane disrupting agent
-
Development asset linked to First People's Hospital in public FDA and regional records. Mechanism: Vasopressin receptor agonist.
- Mechanism
- Vasopressin receptor agonist
-
US regulatory status: approved. Molecular target: Vasopressin receptor.
- Target
- Vasopressin receptor
- Mechanism
- Vasopressin receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor agonist
-
deucravacitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Non-receptor tyrosine-protein kinase TYK2.
- Target
- Non-receptor tyrosine-protein kinase TYK2
- Mechanism
- Tyrosine-protein kinase TYK2 negative allosteric modulator
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
dexmedetomidine
Nervous system (N05)Nervous system (N05) compound in First People's Hospital's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
US regulatory status: approved. Molecular target: Thyroid hormone receptor.
- Target
- Thyroid hormone receptor
- Mechanism
- Thyroid hormone receptor agonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
- Target
- Sodium/potassium-transporting ATPase
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in First People's Hospital's portfolio.
-
US regulatory status: approved. Molecular target: 3',5'-cyclic phosphodiesterase.
- Target
- 3',5'-cyclic phosphodiesterase
- Mechanism
- 3',5'-cyclic phosphodiesterase inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
dolutegravir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
Development asset linked to First People's Hospital in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor agonist.
- Mechanism
- Beta-1 adrenergic receptor agonist
-
dopamine hydrochloride
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-1 adrenergic receptor agonist
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in First People's Hospital's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
doxorubicin hydrochloride
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase-1 inhibitor
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Envelope glycoprotein E.
- Target
- Envelope glycoprotein E
- Mechanism
- Envelope glycoprotein E vaccine antigen
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: Fibroblast growth factor receptor 1.
- Target
- Fibroblast growth factor receptor 1
- Mechanism
- Fibroblast growth factor receptor 1 inhibitor
-
Development asset linked to First People's Hospital in public FDA and regional records.
-
edaravone
Nervous system (N07)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to First People's Hospital in public FDA and regional records. Molecular target: IgG receptor FcRn large subunit p51.
- Target
- IgG receptor FcRn large subunit p51
- Mechanism
- IgG receptor FcRn large subunit p51 antagonist
-
eflornithine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in First People's Hospital's portfolio. Mechanism: Ornithine decarboxylase inhibitor.
- Mechanism
- Ornithine decarboxylase inhibitor